Bile Duct Cancer (Cholangiocarcinoma): Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Cholangiocarcinoma (CCA) is a malignancy arising from the epithelial cells (cholangiocytes) lining the intra- or extrahepatic bile ducts. It is the second most common primary hepatic malignancy globally after hepatocellular carcinoma, with approximately 8,000 new cases per year in the United States and a rising incidence of intrahepatic CCA (iCCA) worldwide. CCA is classified anatomically into three subtypes with distinct surgical approaches, molecular profiles, and prognoses: intrahepatic CCA (iCCA, approximately 20% — arising within the hepatic parenchyma, often presenting as a mass-forming hepatic lesion); perihilar CCA (pCCA, approximately 50% — the Klatskin tumor, arising at the hepatic duct confluence at the porta hepatis, the most common and surgically most complex subtype); and distal extrahepatic CCA (dCCA, approximately 30% — arising in the bile duct below the cystic duct insertion and above the ampulla of Vater, resected with pancreaticoduodenectomy). Prognosis is poor overall — the majority of patients present with unresectable or metastatic disease, with only approximately 20% having resectable disease at diagnosis; 5-year overall survival for resected CCA is 20-40% depending on margins and nodal status. The TOPAZ-1 trial (2022) established gemcitabine plus cisplatin plus durvalumab as the new first-line standard for advanced biliary tract cancer, improving median OS to approximately 12.8 months. Comprehensive molecular profiling at diagnosis is mandatory to identify actionable targets — FGFR2 fusions (pemigatinib/futibatinib), IDH1 mutations (ivosidenib), NTRK fusions (larotrectinib), MSI-H (pembrolizumab), and HER2 amplification (neratinib/trastuzumab) — each with approved or investigational targeted therapies.

CCA risk factors differ markedly by geographic region and CCA subtype, reflecting the interplay of biliary inflammation, oncovirus infection, and molecular oncogenesis. Primary sclerosing cholangitis (PSC): the most important risk factor in Western countries — PSC causes progressive fibrosing inflammation of the intrahepatic and extrahepatic biliary tree, with a lifetime CCA incidence of 10-20%; PSC-related CCA develops at a younger age (median approximately 40 years vs 70 years for sporadic CCA) and is often difficult to detect on surveillance imaging due to the background biliary distortion. Liver flukes: Opisthorchis viverrini (Thailand, Laos) and Clonorchis sinensis (China, Korea) parasites ingested via raw or inadequately cooked freshwater fish colonize the biliary tree and cause decades of chronic biliary epithelial injury through mechanical irritation, biliary obstruction, and secretion of proliferative factors — the dominant CCA risk factor in Southeast Asia (CCA incidence up to 85 per 100,000 in high-prevalence northeast Thailand regions vs 2 per 100,000 globally). Hepatolithiasis: intrahepatic bile duct stones causing chronic biliary inflammation; choledochal cysts (Types I-IV); biliary-enteric anastomoses; Caroli disease (congenital intrahepatic duct dilation). Viral hepatitis: HBV and HCV infection each independently increase iCCA risk approximately 2-4 fold through cirrhosis-mediated inflammatory promotion. Non-alcoholic fatty liver disease (NAFLD) and alcohol-related cirrhosis: emerging risk factors for iCCA, accounting for increasing proportion of iCCA cases in Western countries. Key somatic molecular alterations enabling targeted therapy: FGFR2 gene fusions (approximately 10-15% of iCCA; rare in pCCA and dCCA) — most common fusion partner BICC1 or AHCYL1; IDH1 mutations (approximately 20% of iCCA, codon R132); KRAS mutations (approximately 20-40% of all CCA subtypes); BRAF V600E (rare, approximately 5%); NTRK1/2/3 fusions (approximately 2-4%); HER2 amplification (approximately 5-10% of extrahepatic CCA); TP53 mutations; ARID1A mutations; BRCA1/2 germline mutations (approximately 5%).

Clinical presentation of CCA is determined primarily by anatomical subtype — perihilar and distal CCA obstruct the biliary tree at an earlier clinical stage, while iCCA commonly presents late with large tumor burden. Perihilar and distal CCA: painless progressive obstructive jaundice — the cardinal symptom — manifesting as progressive yellowing of the skin and sclerae, deepening over days to weeks; dark (tea-colored) urine from bilirubinuria; pale (clay or putty-colored) stools from absent fecal urobilinogen; intractable generalized pruritus from bile salt deposition in skin; weight loss (typically 5-10 kg over weeks to months). Right upper quadrant or epigastric pain or discomfort — dull, aching, and persistent. Cholangitis (Charcot's triad: fever with rigors, jaundice, and right upper quadrant pain) when bile duct obstruction is complicated by bacterial superinfection — a medical emergency requiring prompt biliary decompression. Intrahepatic CCA: frequently asymptomatic until the tumor reaches substantial size (>5 cm); may present as an incidentally discovered hepatic mass on imaging performed for another indication; hepatomegaly and a palpable right upper quadrant mass in larger tumors; constitutional features of malignancy — progressive unintentional weight loss, anorexia, fatigue, and low-grade fever. Patients with underlying PSC: new or worsening jaundice beyond baseline PSC-related biliary dysfunction, increased serum CA 19-9, or worsening strictures on MRCP in a PSC patient should always raise suspicion for superimposed CCA. Portal vein invasion and lymph node metastases: jaundice may be accompanied by hepatic failure symptoms (ascites, hepatic encephalopathy). CA 19-9 is elevated (above 37 U/mL) in approximately 60-80% of CCA patients, and in a PSC patient an elevated CA 19-9 above 100 U/mL has high specificity for CCA.

Multiphase CT abdomen/chest (pancreatic/liver protocol with arterial and portal-venous phases) is typically the first imaging modality — defines CCA as a mass (iCCA typically appears as a hypovascular hepatic mass with peripheral rim enhancement and biliary duct dilation) or biliary stricture. MRCP (magnetic resonance cholangiopancreatography) provides high-resolution three-dimensional biliary anatomy, essential for surgical planning in perihilar CCA (Bismuth-Corlette classification I-IVb based on extent of ductal involvement). ERCP with fluoroscopy and biliary brushings for cytological diagnosis: sensitivity for malignant stricture approximately 20-40% for brushings alone; combined with FISH (fluorescence in situ hybridization for chromosomal polysomy/KRAS deletion) improves sensitivity to approximately 55-65%. EUS (endoscopic ultrasound): for lesion characterization and lymph node sampling, particularly for distal CCA; EUS-FNA of hepatic masses for iCCA diagnosis. Percutaneous CT/US-guided liver biopsy for unresectable iCCA when tissue diagnosis is needed for systemic therapy. Serum tumour markers: CA 19-9 (elevated in approximately 75-80% of CCA — note: falsely elevated in biliary sepsis/cholangitis and in Lewis antigen-negative individuals); CEA (less sensitive, elevated in approximately 30%). AJCC 8th edition TNM staging: applied separately for iCCA, pCCA (including Bismuth-Corlette extent and vascular involvement), and dCCA. PET-CT (18F-FDG): detects occult distant nodal and peritoneal metastases missed on CT/MRI in approximately 15-20% of patients, preventing unnecessary laparotomy. Essential comprehensive NGS molecular profiling for all CCA patients at diagnosis: FGFR2 fusion/rearrangement (prefer RNA-based NGS to detect fusion partners), IDH1/IDH2 mutations, KRAS/NRAS/BRAF, NTRK1/2/3 fusions, HER2 amplification/overexpression, RET fusions, MSI/dMMR status, and TMB.

Surgery is the only potentially curative treatment; resectability assessment by an expert hepatobiliary team is the priority. Intrahepatic CCA: hepatic resection (anatomical segmentectomy or major hepatectomy with R0 margins) in approximately 30-40% of cases; portal vein embolization of the planned remnant pre-operatively when future liver remnant (FLR) is below 25-30%; adjuvant capecitabine 1250 mg/m2 BD on days 1-14 of a 21-day cycle for 6 months (BILCAP trial: significant recurrence-free survival benefit). Perihilar CCA: right or left trisectionectomy (extended hepatectomy) including the entire caudate lobe (segment 1, required due to bilateral drainage into the hilar ducts) with bile duct resection and Roux-en-Y hepaticojejunostomy reconstruction; 5-year OS approximately 25-40% for R0 resected pCCA; orthotopic liver transplantation for unresectable perihilar CCA meeting strict Mayo Clinic criteria (tumor diameter at or below 3 cm, no intrahepatic or extrahepatic metastases, CA 19-9 at or below 100 U/mL) with neoadjuvant chemoradiation — 5-year OS approximately 65-70% in selected patients. Distal CCA: pancreaticoduodenectomy (Whipple procedure) with R0 resection; adjuvant capecitabine. Advanced/metastatic CCA — first-line standard: gemcitabine 1,000 mg/m2 IV day 1 plus cisplatin 25 mg/m2 IV day 1 plus durvalumab 1,500 mg IV day 1, every 21 days (TOPAZ-1 trial: OS HR 0.76, p=0.021; median OS 12.8 vs 11.5 months; 24-month OS 24.9% vs 10.4%); gemcitabine plus cisplatin plus tremelimumab plus durvalumab (TOPAZ-1 quadruplet) under investigation. Biomarker-driven second-line targeted therapy: FGFR2 fusion-positive: pemigatinib 13.5 mg orally once daily (21/7 day cycle, FDA-approved, FIGHT-202: ORR 35.5%) or futibatinib 20 mg orally once daily (continuous, FDA-approved, FOENIX-CCA2: ORR 41.7%); IDH1-mutated iCCA: ivosidenib 500 mg orally once daily (ClarIDHy trial: OS HR 0.79, median OS 10.3 vs 7.5 months); MSI-H/dMMR: pembrolizumab 200 mg every 3 weeks; NTRK fusion-positive: larotrectinib or entrectinib; HER2-amplified: neratinib plus trastuzumab or trastuzumab deruxtecan (T-DXd). Biliary drainage: endoscopic biliary stenting (plastic for preoperative drainage, self-expandable metallic stent [SEMS] for palliation) via ERCP for jaundiced patients; percutaneous transhepatic cholangiography (PTC) drainage as alternative when ERCP fails.

Cholangiocarcinoma carries a poor prognosis overall, largely because the majority of patients present with unresectable or metastatic disease. Only approximately 20% of patients have resectable disease at diagnosis, and this is where the best outcomes are achieved. Five-year overall survival for completely resected intrahepatic CCA is approximately 20-40% (R0 resection); for resected perihilar CCA, 5-year survival is approximately 25-40%, dropping sharply when lymph nodes are involved; for resected distal CCA via Whipple procedure, 5-year survival is approximately 25-35%. Liver transplantation for unresectable perihilar CCA meeting Mayo protocol criteria achieves 5-year OS of approximately 65-70% in highly selected patients — the best outcomes in the CCA field. For unresectable or metastatic CCA, the historical median overall survival with gemcitabine-cisplatin was approximately 11-12 months; the TOPAZ-1 trial adding durvalumab improved this to approximately 12.8 months, with 24-month OS of 24.9%. Molecularly targeted therapies have improved outcomes for specific subgroups: FGFR2 fusion-positive iCCA treated with pemigatinib or futibatinib achieves median OS of approximately 18-22 months; IDH1-mutated iCCA treated with ivosidenib achieves median OS of approximately 10 months versus 5.1 months for placebo. MSI-H CCA responds durably to pembrolizumab. By stage: localized resectable CCA carries 5-year survival of 25-40%; locally advanced unresectable CCA has median OS of 8-12 months; metastatic CCA has median OS of approximately 12-14 months with modern systemic therapy. Prognostic factors include R0 resection margin, lymph node involvement, preoperative CA 19-9, and actionable molecular alterations. Recurrence after surgical resection occurs in approximately 50-70% of patients, predominantly in the liver and peritoneum, within the first 2 years.

Patients with primary sclerosing cholangitis (PSC) — the highest-risk Western population — require 6-monthly surveillance with serum CA 19-9 and MRCP/MRI to detect CCA at an early, surgically resectable stage. In Southeast Asia, mass treatment campaigns against liver fluke infection (Opisthorchis viverrini) using praziquantel, combined with improved food safety (avoiding raw freshwater fish), have proven effective in reducing CCA incidence. Treating hepatitis B and C co-infections reduces cirrhosis-related iCCA risk. Surgical resection of symptomatic choledochal cysts — which carry up to 20% lifetime CCA risk — is recommended prophylactically. Maintaining a healthy weight reduces obesity-associated iCCA risk. All CCA patients should undergo comprehensive molecular testing to enable access to targeted second-line therapies.

Progressive painless jaundice — yellowing of the eyes and skin, dark urine, and pale stools — requires urgent evaluation, as biliary obstruction may indicate CCA or another periampullary malignancy. Patients with known PSC who develop new or worsening jaundice, right upper quadrant pain, fever, or an elevated CA 19-9 should be evaluated promptly for CCA on a background of underlying biliary disease. Unexplained weight loss, fatigue, and right-sided abdominal discomfort in the context of chronic liver disease or hepatitis should prompt hepatobiliary assessment including imaging and tumour markers. Anyone who develops painless obstructive jaundice should be assessed within days, as early CCA may be surgically resectable for potential cure, whereas delayed diagnosis often allows progression to unresectable disease. New abnormalities on liver imaging — including a hepatic mass — require specialist hepatobiliary evaluation.